Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023

NEKTAR THERAPEUTICS

Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.
Nektar plans to initiate a Phase 2b study in moderate-to-severe atopic dermatitis in 2023 and explore other auto-immune indications.
Phase 1b data showed dose-dependent improvement over placebo in EASI, EASI-75, vIGA-AD, and Itch NRS with durable response.
Termination does not impact Nektar's cash guidance as milestone payments were not included in forecasts.
CEO Howard Robin expresses confidence in REZPEG's potential as a remittive therapy for atopic dermatitis.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEKTAR THERAPEUTICS terminated License Agreement with Eli Lilly and Company valued at termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald (effective 2023-07-22).

Action: termination
Agreement: license
Counterparty: Eli Lilly and Company
Value: termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald
Effective: 2023-07-22

Exact text from the filing

greement (the “Agreement”) with Eli Lilly and Company (“Lilly”), which Agreement was filed as an exhibit to Nektar’s Quarterly Report on Form 10-Q for the period ended September 30, 2017.

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-23-033020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.